肠道微生物群媒介水平及其与结性脊柱炎疾病活动的关系
Hasan Nasrallah1, Özlem Altındağ2, Mazlum Serdar Akaltun2
1Department of Physical Therapy and Rehabilitation, Medicana Avcilar Hospital, Gaziantep, Türkiye.
Archives of rheumatology
|September 18, 2025
概括
与NSAID相比,接受抗TNF治疗的结性脊髓炎患者的炎症和疾病活性较低. 肠道微生物群标记与临床和炎症标记相关,可能指导新的结性脊髓炎治疗策略.
科学领域:
- 胃肠道学和免疫学
- 类风湿病学 类风湿病学
- 微生物组研究 微生物组研究
背景情况:
- 肠道微生物群对于疾病的发展至关重要.
- 肠道微生物群的变化可能会影响结性脊髓炎 (AS) 的发病和炎症.
- 了解这些变化是有效的AS管理的关键.
研究的目的:
- 评估AS患者与健康个体的肠道微生物群组成.
- 评估微生物改变对AS病原和炎症的影响.
- 根据治疗方法 (抗TNF与NSAIDs) 识别肠道微生物群的差异.
主要方法:
- 与76名AS患者 (抗TNF或NSAID接受者) 与38名健康对照进行了比较.
- 进行了详细的临床评估,包括运动范围和联合检查.
- 测量了炎症标志物 (CRP,ESR) 和CD14,CTLA4,CXC16,LPS和TLR4.4的血清水平.
主要成果:
- 与NSAID组相比,抗TNF组的BASDAI,BASFI,CRP和ESR都较低.
- 与抗TNF和健康组相比,在NSAID接受者中观察到CTLA4,CXC16,LPS和TLR4水平升高.
- 在AS患者和对照人群之间,CD14水平没有显著差异.
结论:
- 与NSAID相比,AS患者的抗TNF治疗与减少炎症和疾病活性有关.
- 肠道微生物群标志物与AS中的临床和炎症标志物相关.
- 这些发现可能有助于理解AS的发病过程,并指导未来的治疗策略.
相关概念视频
Irritable Bowel Syndrome I: Introduction
924
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
924
Chronic Bowel Disorders: Introduction
747
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
747
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499


